Daptomycin doses 8–12 mg/kg are recommended by the Clinical and Laboratory Standards Institute for susceptible dose-dependent (SDD) Enterococcus species.

However, data remain limited regarding safety outcomes of SDD dosing, compared to the standard 4–6 mg/kg dosing approved by the US Food and Drug Administration.

This retrospective cohort study compared safety outcomes of high-dose versus standard-dose daptomycin for enterococcal infections.

High-dose daptomycin was not associated with increased laboratory abnormalities or adverse drug reactions compared to standard-dose daptomycin.

Coupled with previous literature demonstrating daptomycin’s dose-dependent efficacy, these findings support the use of SDD daptomycin dosing.